LIMN NASDAQ
Liminatus Pharma, Inc. Class A Common Stock
1W: -7.1%
1M: +1.6%
3M: -45.3%
YTD: -87.8%
1Y: -95.5%
$3.90
+0.15 (+4.00%)
Weekly Expected Move ±10.0%
$3
$4
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$5.2M
52W Range3.29-141.5
Volume24,301
Avg Volume497,175
Beta0.71
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOChris Kim
Employees1
SectorHealthcare
IndustryBiotechnology
IPO Date2025-05-01
Websiteliminatuspharma.com
12611 Hiddencreek Way
Cerritos, CA 90703
US
Cerritos, CA 90703
US
213 273 5453
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Latest News
Liminatus Pharma regains Nasdaq compliance
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Valetudo Therapeutic | J-Other | 3,448,926 | $0.20 | 2026-07-02 |
| Valetudo Therapeutic | J-Other | 4,373,603 | — | 2026-06-24 |
| Ewon Comfortech Co., | 0 | — | 2026-06-24 | |
| Lemons II Philip Way | 0 | — | 2025-07-10 | |
| Baek Richard JaiHwan | 0 | — | 2025-07-10 |